BioNTech SE – ADR (NASDAQ: BNTX) stock rose 5.64% after reporting its Q3 2021 earnings on November 9, 2021.
The company reported a net profit of €3.2 billion ($3.7 billion) for the three months from July to September 2021 compared to a €210 million ($243 million) loss in Q3 2020.
The German pharmaceutical company generated almost €6.1 billion ($7.1 billion) in revenues during the period compared to €67.5 million ($78 million) in a similar period last year.
The pharmaceutical company’s windfall earnings are derived from its partnership with US pharma giant Pfizer in developing a COVID-19 vaccine that has been distributed globally since December 2020.
BioNTech’s total profit for the first nine months of the year adds up to €7.1 billion (8.2 billion) compared to a €351.7 million ($407 million) loss in a similar period last year.
In reaction to the Q3 earnings report, BioNTech shares rallied 5.64% during premarket trading.
*This is not investment advice.
BioNTech stock price.
The BioNTech stock price rose 5.64% premarket to trade at $259.28, rising from Monday’s slicing price of $242.60.
Should you invest in BioNTech stock?
If you’re a smart investor, you will know that having large-cap stocks in your portfolio is vital. They are more mature companies, considered safer investments, trade with less volatility, have greater analyst coverage, and in most cases, have a steady dividend stream. Due to the current market environment, we think now is the perfect time to add large-cap stocks to your portfolio. But which large-cap shares should you buy? Our stock analysts regularly review the market and share their picks for some of the best large-caps to invest in.